The FDA accepts a New Drug Application for bezuclastinib to treat nonadvanced systemic mastocytosis based on positive data from the SUMMIT trial.
The FDA is expected to decide on treatments for ADHD, Alzheimer disease, breast cancer, diabetes, and myasthenia gravis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results